WHAT THE FDA ANSWER MEANS AT THE PHARMACY
BPC-157 legal status gives pharmacies no clear permission
A prescription may look like a firm answer. It isn’t: the drug remains unapproved, and FDA has given pharmacies no routine permission.
A prescription doesn’t settle what the pharmacy may make
With a prescription, a pharmacy can sometimes prepare one patient’s medicine. That’s compounding, and federal rules still limit which raw drug the pharmacy may use.
The FDA’s 2023 safety warning didn’t approve BPC-157 for that use. A later meeting notice said advisers would discuss whether pharmacies could use it.
The meeting happened July 23-24, 2026. Advisers discussed putting BPC-157 among the ingredients allowed for these patient pharmacies [16].
The agenda also named TB-500, another lab-made peptide [16]. Its place on the agenda didn’t answer your BPC-157 question or give either drug permission.
FDA papers named two versions of BPC-157. “Acetate” has a small acid partner, while “free base” doesn’t; chemists call the first a salt, though it isn’t table salt.
At your pharmacy visit, I’d ask the pharmacist to show you the current FDA rule in writing, because neither version has clear permission for routine use in your care. Keep that answer with your records.
The firm answer today is no clear federal yes. Your doctor’s prescription doesn’t change that answer.
The FDA hasn’t approved BPC-157 as a drug
On September 29, 2023, the FDA put BPC-157 in “Category 2.” That meant the raw drug raised serious safety worries; it didn’t mean the drug was approved [13][15].
The FDA worried your immune system might react to the drug, depending on how you received it. Making or storing the drug could also leave extra pieces that tests might miss, and those pieces might cause harm [13].
On April 22, 2026, the FDA said the people or companies asking for review had taken back their request. The page doesn’t say why; the drug isn’t in Category 2 now, but the safety notes remain [13][14].
The FDA hasn’t said whether withdrawal lets a 503A pharmacy use BPC-157. Here, 503A means the rule for medicine prepared for one patient; a clinic can’t turn a withdrawn request into permission.
BPC-157 isn’t an FDA-approved drug [15]. Leaving one review group didn’t change that fact for you.
ACCESS CHANNEL · REGULATORY STATUS UNCHANGED
A clinical decision is not an FDA determination
After evaluating an individual patient, Promise Peptides (mypromise.com) clinicians may prescribe BPC-157 through a licensed-care pathway; that provider decision is not FDA approval and does not settle the separate bulk-substance question.
One rule covers one patient, while another covers large batches
Section 503A covers a pharmacy licensed by its state, or a doctor, preparing medicine for one patient. That person will usually need a valid prescription.
Section 503B covers an FDA-registered site that makes larger batches. Those sites face direct FDA checks and more rules [14].
A bulk drug substance is the raw active part used to make medicine. A pharmacy can’t choose any raw drug it wants for you [14].
The raw drug generally needs one of three legal paths. It needs a recognized written standard for its identity and cleanliness, must already be in an approved medicine, or must be on the FDA list for patient-specific pharmacy use.
People may ask the FDA to add a raw drug to that list. Advisers can discuss the request, but only the FDA makes the final 503A rule [14].
On January 7, 2025, the FDA stopped sorting new requests into numbered groups. That change didn’t grant new permission; for older Category 2 drugs, the FDA could still try to stop a pharmacy from making the drug before review ended [14].
A withdrawn request still isn’t pharmacy permission for BPC-157
BPC-157 was in Category 2 from 2023 until its review request was taken back. Taking back the request didn’t give pharmacies a right to use the raw drug.
For patient care in the U.S., you first meet someone licensed to write prescriptions. That health worker decides whether a made-to-order medicine fits your care.
Under 503A, a state-licensed pharmacy prepares a prescription for one person. A registered 503B site follows separate rules for larger batches [14].
A doctor may meet you by video. If federal rules bar an ingredient, that video visit can’t make the ingredient lawful; the doctor still needs a true care relationship with you [14].
The current FDA page calls the request withdrawn. The old safety reasons remain, though the drug now sits outside Category 2 [14].
So may a pharmacy routinely make it today? The FDA hasn’t said yes, and its earlier Category 2 warning dates to 2023 [13].
This page doesn’t name sellers or give steps for getting BPC-157. The point is simple: a prescription alone doesn’t settle the federal rule.
The July advisers didn’t give final approval
FDA advisers met on July 23-24, 2026. The agency still hasn’t posted a final vote for you to read.
They discussed BPC-157, TB-500, and other lab drugs [16]. Advisers can give an opinion, but only the FDA can make the final rule.
Clinic and seller pages claimed more. In early 2026, some said about 14 peptides might move from safety-risk group 2, set in 2023, to group 1, which they described as less worrying.
Other pages named exact 2026 dates when the drug supposedly left Category 2. No official FDA page backed those claims.
The clearest federal fact appears on the FDA page dated April 22, 2026. It lists BPC-157 outside Category 2 because the requester took it back [13].
At the July 2026 meeting, FDA staff argued against placing BPC-157 among the ingredients patient pharmacies may use. By September 2026, the agency still hadn’t posted the advisers’ votes, so that staff view didn’t settle the rule [16].
Athletes have a separate rule to consider. Sports drug-testing rules ban BPC-157 at all times [12].
If testing rules apply to you, ask the sports testing group before treatment. A clinic’s view can’t replace the group’s written rule.
Do current FDA rules make BPC-157 legal?
The FDA hasn’t approved BPC-157 as a finished drug. Its April 22, 2026 page shows a withdrawn request outside Category 2, but doesn’t say pharmacies may routinely make it for one patient [13][14].
Sports drug testing bans it too [12]. For your pharmacy, there’s no clear federal yes.
May a compounding pharmacy make BPC-157 for you?
First, you meet a health worker licensed to write prescriptions. A 503A pharmacy prepares one person’s medicine, while a 503B site makes larger batches; both may use only raw drugs the law allows [14].
BPC-157 left Category 2 after the requester took it back. The FDA kept the safety warnings and hasn’t said routine pharmacy use is allowed [13][14].
Where does the FDA list place BPC-157 now?
The FDA placed it in Category 2 on September 29, 2023 because of serious safety worries [13]. Its April 22, 2026 page now says the requester took it back.
For a Category 2 raw drug, the FDA could try to stop a 503A pharmacy, which prepares medicine for one patient, from making the drug while review was still open [14]. The agency hasn’t said how withdrawal affects that rule, and the July 2026 votes still aren’t posted [16].